Valuation: Codexis, Inc.

Market Cap 205M 179M 166M 153M 289M 19.57B 295M 1.98B 777M 9.61B 768M 751M 33.2B P/E 2026 *
-5.82x
P/E 2027 * -7.81x
Enterprise Value 205M 179M 166M 153M 289M 19.57B 295M 1.98B 777M 9.61B 768M 751M 33.2B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.3x
Free-Float
92.59%
Yield 2026 *
-
Yield 2027 * -
1 day-7.41%
1 week-15.41%
Current month-0.44%
1 month-6.25%
3 months-2.17%
6 months+31.58%
Current year+38.04%
1 week 2.22
Extreme 2.225
2.66
1 month 2.18
Extreme 2.175
2.7
Current year 0.96
Extreme 0.9583
2.98
1 year 0.96
Extreme 0.9583
3.87
3 years 0.96
Extreme 0.9583
6.08
5 years 0.96
Extreme 0.9583
42.01
10 years 0.96
Extreme 0.9583
42.01
Manager TitleAgeSince
Chief Executive Officer 59 2025-11-06
Director of Finance/CFO 59 2024-09-29
Chief Tech/Sci/R&D Officer 56 2020-05-04
Director TitleAgeSince
Director/Board Member 66 2016-02-29
Director/Board Member 59 2025-11-06
Chairman 66 -
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Director

66,350 0.0730%
06-16Free

Director

66,350 0.0730%
06-16Free

Director

66,350 0.0730%
Change 5-day change 1-year change 3-year change Capi.($)
-7.41%-15.41%-24.75%-28.12% 205M
+0.44%+1.41%+4.36%+10.81% 50.61B
-1.57%-3.18%+383.82%+593.37% 39.11B
-0.14%+0.77%+27.49%-5.50% 34.64B
+1.76%-1.78%+21.44%+53.38% 33.79B
-0.06%-0.45%+2.94%+28.70% 26.89B
-1.93%-1.01% - - 16.47B
-1.49%-6.18%+63.89%+120.53% 15.14B
+0.78%+1.16%+14.69%+17.32% 13.85B
-0.97%-2.83%+10.35%-33.29% 12.72B
Average -1.06%-1.50%+56.03%+84.13% 24.34B
Weighted average by Cap. -0.18%-1.08%+80.56%+122.37%

Financials

2026 *2027 *
Net sales 74.1M 64.99M 60.19M 55.39M 105M 7.09B 107M 717M 281M 3.48B 278M 272M 12.03B 88.93M 78M 72.24M 66.47M 126M 8.51B 128M 861M 338M 4.18B 334M 327M 14.44B
Net income -35.29M -30.95M -28.67M -26.38M -49.89M -3.38B -50.86M -342M -134M -1.66B -133M -130M -5.73B -26.56M -23.29M -21.57M -19.85M -37.55M -2.54B -38.28M -257M -101M -1.25B -99.73M -97.55M -4.31B
Net Debt - -
Logo Codexis, Inc.
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Employees
146
Date Price Change Volume
26-07-13 US$2.250 -7.41% 579,667
26-07-10 US$2.430 -5.08% 550,515
26-07-09 US$2.560 -1.54% 494,152
26-07-08 US$2.600 0.00% 536,290
26-07-07 US$2.600 -2.26% 774,272
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.250USD
Average target price
6.583USD
Spread / Average Target
+192.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDXS Stock